Femasys (FEMY) announced the appointment of Kelley Nicholas as Chief Commercial Officer, CCO. Nicholas will be responsible for leading the execution and optimization of Femasys’ commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on expanding the U.S. infertility market and building key international partners. Prior to joining Femasys, Nicholas served as Head of Sales at NeuroPace (NPCE)
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- Femasys: Strategic Partnerships and Revenue Growth Drive Buy Rating with $12 Price Target
- Femasys announces partnership with Carolinas Fertility Institute
- Femasys Announces Public Offering and Private Placement
- Femasys prices 3.6M shares at 85c in underwritten public offering
- Femasys announces common stock offering, no amount given